Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas
Corroborated by 1 source from 1 publisher
globalgeneral3/14/2026
TL;DR
According to finance.yahoo.com, iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas Among the first six evaluable patients, the therapy demonstrated a 50% objective response rate, with patients experiencing deep responses that improved over time despite a high baseline disease burden and multiple prior lines of therapy.